Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy [Phase 2, Phase 3]

View source ↗

Summary

A pediatric Phase 2/3 trial evaluating oral ozanimod for moderately to severely active Crohn's disease has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Crohn Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-04-22